Smoking and tea consumption delay onset of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue 1, 2009, Pages 41-46

  Kandinov, Boris ^a   Giladi, Nir ^a,b   Korczyn, Amos D ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Age of onset; Coffee; Cup years; Neuroprotection; Pack years; Parkinson's disease; Smoking; Tea

Indexed keywords

AGED; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COFFEE; FEMALE; HUMAN; MALE; MIDDLE AGED; ONSET AGE; PARKINSON DISEASE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK; SMOKING; TEA;

AGE OF ONSET; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COFFEA; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SMOKING; TEA;

EID: 63049113290     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.02.011     Document Type: Article

References (62)

1. Dorn HF. The mortality of smokers and nonsmokers. In: Proceedings of the social statistics section, vol 1. American Statistical Association; 1958. p. 34-71.
2. Dorn HF. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep 1959;74:581-93.
3. Kahn HA. The Dorn study of smoking and mortality among US veterans: report on eight and one-half years of observation. In: Haenszel W, editor. Epidemiologic approaches to the study of cancer and other chronic diseases. National Cancer Institute Monograph, vol 19. Bethesda, MD: US Department of Health, Education and Welfare; 1966. p. 1-25.
4. Hammond EC. Smoking in relation to the death rates of one million men and women. In: Haenszel W, editor. Epidemiologic approaches to the study of cancer and other chronic diseases. National Cancer Institute Monograph, vol 19. Bethesda, MD: US Department of Health, Education and Welfare; 1966. p. 127-204.
5. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson's disease. Am J Epidemiol 1968;88:149-58.
6. Kessler II , Diamond EL. Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: a survey and explanatory hypothesis. Am J Epidemiol 1971;94:16-25.
7. Kessler II . Epidemiologic studies of Parkinson's disease. III. A community-based survey. Am J Epidemiol 1972;96:242-54.
8. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chronic Dis 1975;28:493-7.
9. Doll R, Peto R. Mortality in relation to smoking: 20 years observations on male British doctors. BMJ 1976;2:1525-36.
10. Baumann RJ, Jameson HD, Mckean HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson's disease: a comparison of cases with matched neighbors. Neurology 1980;30:839-43.
11. Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:577-81.
12. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-24.
13. Marttila RJ, Rinne UK. Smoking and Parkinson's disease. Acta Neurol Scand 1980;62:322-5.
14. Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA. Nicotine exposure and Parkinson's disease. Am J Epidemiol 1981;114:191-200.
15. Golbe LI, Cody RA, Duvoisin RC. Smoking and Parkinson's disease. Search for a dose-response relationship. Arch Neurol 1986;43:774-8.
16. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology 1987;37:226-32.
17. Aquilonius S-M. Parkinson's disease - etiology and smoking. Prog Brain Res 1989;79:329-33.
18. Riggs JE. Cigarette smoking and Parkinson's disease: the illusion of a neuroprotective effect. Clin Neuropharmacol 1992;15:88-99.
19. Tanner CM, Chen B, Wang WZ, Peng ML, Liu ZL, Liang XL, et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci 1987;14:419-23.
20. Sasco AJ, Paffenbarger RS. Smoking and Parkinson's disease. Epidemiology 1990;1:460-5.
21. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-80.
22. Tzourio C, Rocca WA, Breteler MM, Baldereschi M, Dartigues JF, Lopez-Pousa S, et al. Smoking and Parkinson's disease. An age-dependent risk effect? Neurology 1997;49:1267-72.
23. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. Mov Disord 1999;14:928-39.
24. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993;43:1150-8.
25. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994;139:1129-38.
26. De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord 1996;11: 17-23.
27. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583-8.
28. Hellenbrand W, Seidler A, Robra B-P, Vieregge P, Oertel WH, Joerg J, et al. Smoking and Parkinson's disease: a case-control study in Germany. Int J Epidemiol 1997;26:328-39.
29. Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology 1998;19:709-12.
30. Gorell JM, Rybicki A, Johnson CC, Peterson CL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999;52:115-9.
31. Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson's disease in Indian patients. J Neurol Sci 2001;190:49-55.
32. Tan EK, Tan C, Fook-Chong SMC, Lum SY, Chai A, Chung H, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 2003;216:163-7.
33. Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. Risk factors for Parkinson's disease: case-control study in the province of Caceres, Spain. Acta Neurol Scand 1994;89:164-70.
34. Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, et al. Diet and Parkinson's disease I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food frequency questionnaire in a case-control study. Neurology 1996;47:636-43.
35. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 1999;14:28-37.
36. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000;55:1350-8.
37. Preux PM, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, et al. Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. Neuroepidemiology 2000;19:333-7.
38. Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study. Mov Disord 1992;7:339-44.
39. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth Jr WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002;155:732-8.
40. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 2000;283:2674-9.
41. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
42. Chan DKY, Woo J, Ho SC, Pang CP, Law LK, Ng PW, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry 1998;65:781-4.
43. Kandinov B, Giladi N, Korczyn AD. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. Parkinsonism Relat Disord 2007;13:243-5.
44. Hughes AJ, Daniel SE, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
45. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
46. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Blackwell Scientific Publications; 1987.
47. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002;73:529-34.
48. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
49. Hancock BD, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007;64:576-80.
50. Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, et al. A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology 1986;36:284-8.
51. Diana JN. Tobacco smoking and nutrition. Ann N Y Acad Sci 1993;686:1-11.
52. Seppa T, Ahtee L. Comparison of the effects of epibatidine and nicotine on the output of dopamine in the dorsal and ventral striatum of freelymoving rats. Arch Pharmacol 2000;362:444-7.
53. Minana MD, Montoliu C, Llansola M, Grisoli{dotless}́a S, Felipo V. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology 1998;37:847-57.
54. Quik M, Jeyarasasingam G. Nicotinic receptors and Parkinson's disease. Eur J Pharmacol 2000;393:223-30.
55. Linert W, Bridge MH, Huber M, Bjugstad KB, Grossman S, Arendash GW. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's disease. Biochem Biophys Acta 1999;1454:143-52.
56. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor RR, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379:733-6.
57. Caldwell CR. Oxygen radical absorbance capacity of the phenolic compounds in plant extracts fractionated by high-performance liquid chromatography. Anal Biochem 2001;293:232-8.
58. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-44.
59. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001;78:1073-82.
60. Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against abeta toxicity and PKC dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 2003;17:952-4.
61. Svenningsson P, Le Moine C, Fapisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999;59:355-96.
62. Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry 2007;62:1353-62.